PETCT and lung cancer: Selecting those likely to benefit and sparing those with little to gain

Lung cancer is the third commonest cancer in the UK and 75% of patients present with advanced disease (stage III or IV); 10-year survival is only 5%.

PETCT is best considered as a tool that aids the selection of those most likely to benefit from potentially curative treatment, either surgical resection or radical radiotherapy, while sparing those whose disease is so advanced that this approach would be futile.

The content on this page is provided by the individuals concerned and does not represent the views or opinions of RAD Magazine.